P3 Health Partners INC 8-K filings

P3 Health Partners announced robust second quarter 2026 financial results, including a significant increase in Adjusted EBITDA and an upward revision of full-year guidance.

P3 Health Partners Inc. subsidiary P3 Health Group, LLC has amended its Repurchase Promissory Note with IHC Health Services, Inc., extending the maturity date to September 30, 2028, and implementing a 14% PIK interest rate.

P3 Health Partners Inc. has successfully regained compliance with Nasdaq's continued listing requirements, as confirmed by a recent notification from Nasdaq.

P3 Health Partners has addressed Nasdaq delisting concerns by converting $252.5 million in debt to preferred equity and raising $30 million in new capital.

P3 Health Partners announced first quarter 2026 financial results, reporting $26 million in adjusted EBITDA and raising full-year adjusted EBITDA guidance to a midpoint of $40 million.

P3 Health Partners has entered into a debt exchange and $70 million capital raise to regain Nasdaq listing compliance.

P3 Health Partners announced Q4 and full-year 2025 results, projecting a significant Adjusted EBITDA improvement and a path to profitability in 2026.

P3 Health Partners, LLC has entered into a significant Master Services Agreement and Statement of Work with a large Nebraska nonprofit health insurer to provide comprehensive support for its Medicare Advantage network.

P3 Health Partners Inc. received a notice from Nasdaq regarding non-compliance with its minimum stockholders' equity listing rule, initiating a 45-day period to submit a compliance plan.

P3 Health Partners reported a 5% revenue decrease to $345.3 million in Q3 2025, alongside a $45.9 million Adjusted EBITDA loss, as it navigates a transitional year with strategic membership reductions.

P3 Health Partners Inc. announced the formation of P3 Commonwealth Innovation MSO, LLC, a new entity with Commonwealth Primary Care ACO, LLC, to manage and coordinate accountable care organization activities.

P3 Health Partners Inc. has amended its term loan agreement, extending the maturity date to December 31, 2027, and modifying interest and principal payment terms.

P3 Health Partners announced a Q2 2025 net loss of $43.7 million and a 6% revenue decline, but highlighted flat medical costs and significant 2026 EBITDA opportunities.

P3 Health Partners Inc. reported the resignation of Dr. Sherif Abdou from its Board of Directors and the subsequent appointment of its Chief Executive Officer, Dr. Aric Coffman, to fill the vacancy.

P3 Health Partners Inc. announced that all four proposals, including the election of three Class I directors and the ratification of its independent auditor, were approved by stockholders at its 2025 Annual Meeting.

P3 Health Partners Inc. has entered into a new financing agreement for up to $70 million in unsecured, subordinated debt with an affiliate of its principal stockholder, featuring a 19.5% annual interest rate largely payable in kind, alongside warrants for Class A Common Stock.

P3 Health Partners reported its Q1 2025 financial results, showing a mix of decreased revenue and membership but affirmed its 2025 guidance, highlighting progress in its turnaround plan.

P3 Health Partners implemented a 1-for-50 reverse stock split of its Class A and Class V common stock, effective April 11, 2025, to increase its stock price and maintain Nasdaq compliance.

P3 Health Partners Inc. announces a 1-for-50 reverse stock split of its common stock, effective April 11, 2025.

P3 Health Partners Inc. stockholders approved a reverse stock split proposal at a Special Meeting held on March 31, 2025.

P3 Health Partners announces an 18% increase in revenue for 2024, reaching $1.50 billion, while affirming its financial outlook for 2025.

P3 Health Group, LLC, a subsidiary of P3 Health Partners Inc., has entered into a financing agreement with VBC Growth SPV 4, LLC, involving an unsecured promissory note for up to $30 million and warrants to purchase Class A Common Stock.

P3 Health Partners provides preliminary 2025 revenue and Adjusted EBITDA guidance, along with plans for a $30 million financing transaction with its largest shareholder.

P3 Health Partners subsidiary, P3 Health Group, LLC, has entered into a financing agreement for up to $25 million and refinanced an existing promissory note.

P3 Health Partners announced a 26% year-over-year revenue increase to $362.1 million for the third quarter of 2024, but experienced significant losses due to lower risk adjustments and higher medical expenses.

P3 Health Partners has announced the appointment of Leif Pedersen as its new Chief Financial Officer, effective October 1, 2024, succeeding Atul Kavthekar.

P3 Health Partners announced a 15% increase in revenue for the second quarter of 2024, but also reported a decrease in gross profit and an adjusted EBITDA loss.

P3 Health Partners Inc. held its 2024 Annual Meeting of Stockholders on June 6, 2024, where all proposed directors were elected and all proposals were approved.

P3 Health Partners Inc. has successfully completed a private placement, raising approximately $42.2 million and has amended its agreement with Chicago Pacific Founders, extending a standstill period.

P3 Health Partners has entered into a securities purchase agreement to raise $42.2 million through a private placement, which includes the issuance of common stock and warrants, and has extended its standstill agreement with Chicago Pacific Partners.